These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 22266575

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment.
    Kliger AS, Fishbane S, Finkelstein FO.
    Clin J Am Soc Nephrol; 2012 Feb; 7(2):354-7. PubMed ID: 22266571
    [Abstract] [Full Text] [Related]

  • 7. It's time to compare anemia management strategies in hemodialysis.
    Coyne DW.
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
    [Abstract] [Full Text] [Related]

  • 8. Anemia trials in CKD and clinical practice: refining the approach to erythropoiesis-stimulating agents.
    de Francisco ALM, Piñera C.
    Contrib Nephrol; 2011 Apr; 171():248-254. PubMed ID: 21625120
    [Abstract] [Full Text] [Related]

  • 9. An economic evaluation of erythropoiesis-stimulating agents in CKD.
    Clement FM, Klarenbach S, Tonelli M, Wiebe N, Hemmelgarn B, Manns BJ.
    Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Hemoglobin levels triggering erythropoiesis-stimulating agent therapy in patients with cancer: the shift after United States Food and Drug Administration policy changes.
    Stroupe KT, Tarlov E, Lee TA, Weichle TW, Zhang QL, Michaelis LC, Ozer H, Durazo-Arvizu R, Browning MM, Hynes DM.
    Pharmacotherapy; 2012 Nov; 32(11):988-97. PubMed ID: 23108695
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
    Arbuckle RB, Griffith NL, Iacovelli LM, Johnson PE, Jorgenson JA, Kloth DD, Lucarelli CD, Muller RJ.
    Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
    [Abstract] [Full Text] [Related]

  • 16. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.
    Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL.
    Am J Kidney Dis; 2013 Jan; 61(1):44-56. PubMed ID: 22921639
    [Abstract] [Full Text] [Related]

  • 17. The Use of Erythropoiesis-Stimulating Agents in Patients With CKD and Cancer: A Clinical Approach.
    Thavarajah S, Choi MJ.
    Am J Kidney Dis; 2019 Nov; 74(5):667-674. PubMed ID: 31395400
    [Abstract] [Full Text] [Related]

  • 18. Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study.
    Seliger S, Fox KM, Gandra SR, Bradbury B, Hsu VD, Walker L, Chiou CF, Fink JC.
    Clin J Am Soc Nephrol; 2010 May; 5(5):882-8. PubMed ID: 20299377
    [Abstract] [Full Text] [Related]

  • 19. Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease.
    Seliger SL, Zhang AD, Weir MR, Walker L, Hsu VD, Parsa A, Diamantidis CJ, Fink JC.
    Kidney Int; 2011 Aug; 80(3):288-94. PubMed ID: 21389972
    [Abstract] [Full Text] [Related]

  • 20. [Regarding the optimal hemoglobin target range in renal anemia].
    Maurin N.
    Med Klin (Munich); 2008 Sep 15; 103(9):633-7. PubMed ID: 18813886
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.